Rite Aid has sold the pharmacy operations of more than 1,000 of its U.S. stores to major competitors, including CVS Health Corporation (NYSE:CVS), Walgreens, Albertsons, and Kroger, as part of its ongoing Chapter 11 bankruptcy process.Rite Aid to Sell Majority of U.S. Pharmacy Operations to Rivals, Including CVS Health Corporation (CVS)

CVS Health Corporation (NYSE:CVS) emerged as the largest buyer, acquiring prescription records from over 600 Rite Aid locations across 15 states, and agreeing to purchase 64 physical stores in Idaho, Oregon, and Washington. The deals are pending approval from the bankruptcy court.

Despite the asset sales, Rite Aid stated that its stores remain open and customers can continue using its pharmacy services without disruption. CEO Matt Schroeder said that the agreements will allow pharmacy customers to transition smoothly while also helping retain some employees. He emphasized that the move ensures customers will continue receiving the pharmacy care and services they need without any disruptions.

The added stores would help CVS Health Corporation (NYSE:CVS) expand its footprint in an area where it currently has fewer locations relative to the population compared to other parts of the country. This offers a strategic expansion opportunity for the company. Alongside strengthening its foothold in the retail pharmacy market, CVS is also drawing investor interest thanks to its consistent dividend payments. The company has maintained consistent payments since 1997 and currently offers a quarterly dividend of $0.665 per share. As of May 18, the stock has a dividend yield of 4.25%.

While we acknowledge the potential of CVS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than CVS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Mid-Cap Dividend Aristocrats to Invest in Now and Dividend Challengers 2025: Top 25

Disclosure. None.

View Comments